Bioequivalence Study of Antihyperlipidemic in Human Volunteers: Bioequivalence study of Antihyperlipidemic drug Finofibrate in healthy human volunteers

Finofibrate is an oral antihyperlipemic agent. In this investigation, we report randomized, single dose, open-label, three-treatment, three-period, three-sequence, crossover Clinical study in healthy 18 adult male human volunteers evaluating the bioequivalence of two new investigational formulation of Finofibrate 145 mg Tablets (manufactured by manufactured by Wockhardt Limited, India) and reference formulation ‘Finofibrate ® ‘145 mg Tablet (® indicates reference formulation). In this investigation, we report randomized, single dose, open-label, three-treatment, three period, three-sequence, crossover Clinical study evaluating the bioequivalence of two new investigational formulation of Finofibrate 145 mg Tablets (manufactured by manufactured by Wockhardt Limited, India) and reference formulation ‘Finofibrate ® ‘145 mg Tablet (® indicates reference formulation). Pharmacokinetic parameters were investigated and statistical analysis was done.